Dimethyl fumarate with slow titration improves treatment satisfaction and quality of life in Iranian MS patients

This evidence comes from a multicenter, phase 4, open-label, single-arm observational study conducted in Iran. The study population comprised 645 patients with relapsing-remitting multiple sclerosis (RRMS) who were initiating treatment with dimethyl fumarate (DMF). Participants were either treatment-naïve or switching from prior injectable disease-modifying therapies. The study followed these patients for 12 months in a real-world clinical setting, with no randomized comparator group; all outcomes were compared to patient baseline status prior to DMF initiation.

The intervention was oral dimethyl fumarate administered with a specified slow-dose titration regimen. The exact dosing protocol (e.g., starting dose, titration schedule, and maintenance dose) was not reported in the provided data. As a single-arm study, the formal comparator was each patient's own baseline assessment across all measured parameters. The study's primary focus was on patient-reported outcomes rather than traditional clinical efficacy measures like relapse rate or MRI activity.

The primary outcome was the change in treatment satisfaction from baseline to month 12 among previously treated patients, measured by the Treatment Satisfaction Questionnaire for Medication (TSQM-14). Results showed statistically significant improvements across all TSQM-14 domains: effectiveness (increase of +13.01 points, p < 0.001), side effects (increase of +7.76 points, p < 0.001), convenience (increase of +35.21 points, p < 0.001), and global satisfaction (increase of +15.75 points, p < 0.001). The magnitude of improvement was largest for the convenience domain. Absolute numbers for these scores were not reported.

Key secondary outcomes also showed statistically significant favorable changes. Health-related quality of life measured by the EQ-5D-3L showed a utility score improvement of +0.07 (p < 0.001) and a Visual Analogue Scale (VAS) improvement of +3.86 points (p < 0.001). Sleep quality measured by the Pittsburgh Sleep Quality Index (PSQI) improved, with a score reduction of -1.62 points (p < 0.001), indicating better sleep. Work productivity measured by the Work Productivity and Activity Impairment (WPAI) questionnaire showed a -7.55% change in absenteeism (p < 0.001). Depressive symptoms improved significantly (BDI-7 change −0.11, p<0.001).

Adverse events declined over time, confirming a favorable and manageable safety profile. Gastrointestinal adverse events led to discontinuation in 45 patients (26.0%). The reported improvement in the TSQM-14 'side effects' domain suggests a perceived benefit, but without absolute safety data, a full tolerability profile cannot be assessed from this evidence alone.

These results add a patient-centered perspective to the existing body of evidence for DMF in RRMS. Prior landmark randomized controlled trials (DEFINE and CONFIRM) established DMF's efficacy in reducing relapse rates and MRI lesions. This observational study suggests that in a real-world Iranian population, initiating DMF—particularly with a slow titration—is associated with meaningful improvements in how patients perceive and experience their treatment, which complements the known efficacy data. The large improvement in convenience likely reflects the transition from injectable therapies to an oral medication.

Key methodological limitations must be considered. As an open-label, single-arm, observational study without a control group, the observed improvements cannot be definitively attributed to DMF alone; they may be influenced by placebo effects, regression to the mean, or the natural course of the disease. The study was conducted solely in Iran, which may limit generalizability to other geographic and healthcare settings. The absence of reported clinical efficacy endpoints (relapses, disability progression, MRI) means the correlation between improved patient-reported outcomes and disease control is unknown. Furthermore, the lack of detailed safety reporting is a significant gap.

The clinical implications are that for patients with RRMS in similar settings, a slow titration of DMF may be associated with improved treatment satisfaction and quality of life over 12 months, especially for those switching from injectables. Clinicians might consider these patient-reported benefits when discussing treatment options, while continuing to monitor for known safety signals like lymphopenia and GI intolerance. However, treatment decisions should still be primarily guided by efficacy and safety data from controlled trials.

Several important questions remain unanswered. How do these patient-reported outcomes correlate with clinical and radiological disease activity? What were the specific adverse event rates and reasons for discontinuation? How does the slow titration regimen used compare to standard titration in terms of tolerability and efficacy? Would these results be replicable in a controlled trial with a comparator arm? Long-term data beyond 12 months are also needed to see if these improvements are sustained.